Research
The questions this market does not answer
Some questions about a seller can be settled from a public page in a minute. Others cannot be settled at all, and the split between the two is not random. It follows where a duty to publish exists.
Four questions have public answers, and they are the same four every time
Reading a peptide seller from outside, four things can be established from its own pages without asking anyone.
Whether it names the compounding pharmacy that fills the prescription. Whether it posts a price. Whether it publishes a list of the states it serves. And whether bloodwork is included in that price.
Those four are not a considered assessment of a company. They are simply the questions that a public page can answer, which is a smaller set than the questions a buyer has.
A no on any of them means the seller does not publish that fact. It is not a finding that the company does the opposite, and it should not be read as one.
What the counting found
Across the 38 sellers tracked here in September 2026, ten name the compounding pharmacy that fills a prescription.
Two include bloodwork in the published price.
Seventeen publish no state-coverage list at all. Another seventeen publish a full fifty-state list, and four publish a partial one.
Every one of the 38 posts a price somewhere. One publishes all four facts.
Those figures move when the roster does, and the version kept current on this site is computed rather than written, so it changes on its own when a seller is added.
A published price is not the same as a comparable one
Price is the fact this market publishes most reliably, and it is also the one that means the most different things.
The 38 sellers advertise 215 compound offerings between them and publish 177 price figures. Sixteen of them advertise an offering with no figure a reader can find, covering 52 such pairings.
The 177 figures carry 134 distinct qualifying phrases between them. None is a plain monthly rate with nothing attached, and the shortest phrase in the whole set is a starting rate.
Forty of the figures are a starting rate. Thirteen are a vial price rather than a period. Fifteen exist only as part of a combination, because the compound is not sold separately at all.
So the honest reading of a price on a product page is that it is a number plus a sentence, and the sentence is the part that decides whether two sellers can be compared.
Why the unanswered questions stay unanswered
The pattern is not carelessness on the part of sellers. It follows the shape of the rules.
The federal section that governs pharmacy compounding sets out who may compound, from what substances, under what conditions. Read end to end, it contains no requirement to disclose anything to a buyer, no requirement to notify one, and no requirement to publish anything on a website.
Its publication duties run the other way. They are duties on the Secretary to publish lists, not duties on a pharmacy to publish anything about itself.
That is a statement about one federal section, measured rather than assumed. State pharmacy law and state telehealth law were not surveyed here, and they are where many of the duties a patient meets in practice actually live.
The effect is still visible in the market. A fact with no publication duty attached to it gets published by the sellers who choose to, which is why the pharmacy question splits a roster instead of being answered by all of it.
Where a publication duty does exist, it is about the money
One clear federal duty to tell a buyer something does apply here, and it covers the commercial side rather than the clinical one.
For an internet sale through a negative option feature, a seller has three duties. It has to provide text that clearly and conspicuously discloses all material terms of the transaction before obtaining billing information. It has to obtain express informed consent before charging, and provide simple mechanisms to stop recurring charges.
Material terms of the transaction is the operative phrase. It reaches the price, the interval, the renewal and the exit. It does not reach the identity of the pharmacy, the origin of the active ingredient, or who read your intake.
That asymmetry explains a lot of what a checkout feels like. The parts of the purchase governed by consumer law are laid out; the parts governed by professional practice are described in whatever words the seller chose.
The questions that stay open
Which pharmacy will fill the order, and whether it is a state-licensed compounding pharmacy or a registered outsourcing facility.
Where the active ingredient came from, and what was tested on the batch that ends up in your vial.
Who read your intake, what license they hold, and in which state they hold it.
What happens to the money if a prescriber declines after the card has been charged.
What a cancellation actually ends, and what it leaves running.
None of those is exotic. Each of them is answerable by the seller in one sentence, and none of them is answerable by a reader from outside unless the seller chooses to write that sentence down.
What to do with a question that has no published answer
Ask it before paying, in writing, and keep what comes back.
A written answer changes the situation in a way that reading the site cannot. It is specific, it is dated, and it is a statement the seller made to you rather than a statement it made to nobody in particular.
A refusal to answer in writing is also information, and it arrives before the money moves rather than after.
The difference between a seller that publishes little and a seller that will not say is worth more than any of the four public facts on their own.
Key takeaways
- Four facts about a seller can be settled from a public page: the pharmacy named, the price posted, the coverage list, and whether labs are included.
- Of the 38 sellers tracked here in September 2026, ten name the pharmacy, two include labs, seventeen publish no coverage list, and one publishes all four facts.
- All 38 post a price, and the 177 published figures carry 134 distinct qualifying phrases between them.
- A no in any of these columns means a fact was not published, never that a seller does the opposite.
- The federal pharmacy compounding section, read in full, imposes no duty to disclose or publish anything to a buyer.
- The clear federal disclosure duty here covers the commercial terms of the transaction, not the clinical facts behind it.
Frequently asked questions
Why do so many sellers not name their compounding pharmacy?
The federal section governing pharmacy compounding, read end to end, contains no duty to disclose anything to a buyer and no duty to publish anything on a website. Its publication requirements are duties on the Secretary to publish lists, not duties on a pharmacy to identify itself to patients. Naming the pharmacy is therefore a choice. State law was not surveyed here and may impose duties of its own.
Is a missing answer a warning sign?
Not by itself. A seller that does not publish the name of its pharmacy may use a perfectly ordinary one, and what can be checked from outside is only whether it says so. The useful signal is not the gap. It is what happens when you ask the question directly and ask for the answer in writing.
What is a seller actually required to tell me before it takes my money?
For an internet sale through a negative option feature, federal law requires three things of a seller. The first is text that clearly and conspicuously discloses all material terms of the transaction before your billing information is obtained. The second is express informed consent before the charge, and the third is simple mechanisms to stop recurring charges. That duty covers the commercial terms of the purchase. It does not extend to the clinical facts about who fills the order or who reviews the request.
Why is a published price still hard to compare?
Because the number rarely travels alone. Across the price figures published by the sellers tracked here in September 2026, there were more than a hundred distinct qualifying phrases. The shortest of them is a starting rate, and none is a plain monthly figure with nothing attached. Some are starting rates, some are vial prices rather than periods, and some exist only as part of a combination the compound is sold in. The qualifier is the part that decides comparability.
What should I ask for in writing?
The pharmacy that will fill the order and whether it is a compounding pharmacy or an outsourcing facility. The license type and state of the person who reviews your intake. What happens to the payment if a prescriber declines. What canceling ends and what it leaves in place. Each of those is one sentence to answer, and the answer is a dated statement made to you.
Do these counts stay accurate?
They are a reading of the sellers tracked here in September 2026, and they change as sellers are added or as a seller changes what it publishes. The seller-by-seller version on this site is computed from the same underlying record rather than written out, so it updates when the record does. Where the two disagree, the computed table is the current one.
Sources
Each document below is named as it names itself, with the date printed on that document rather than the day it was read.
- United States Code Title 21, Section 353a, Pharmacy compounding, read in full and searched for any duty to disclose, notify, advertise or publish to a patient, 2024 Main Edition — Office of the Law Revision Counsel, U.S. House of Representatives, January 2025
- United States Code Title 15, Section 8403, Negative option marketing on the Internet, 2024 Main Edition — Office of the Law Revision Counsel, U.S. House of Representatives, January 2025